There are 2789 resources available
1799TiP - HGCSG2002: A prospective multicenter observational biomarker study of microbiome for nivolumab treatment in advanced esophageal cancer
Presenter: Shintaro Nakano
Session: ePoster Display
1803P - The differences of TMB scores could be found in patients with different tumor types or pathological types
Presenter: Chenyue Zhang
Session: ePoster Display
1804P - Baseline mutational profiles of patients (pts) with carcinoma-of-unknown-primary-origin (CUP) enrolled onto CUPISCO
Presenter: Christoph Benedikt Westphalen
Session: ePoster Display
1805P - Assistance with an artificial intelligence-powered PD-L1 analyzer reduces interobserver variation in pathologic reading of tumor proportion score in non-small cell lung cancer
Presenter: Sangjoon Choi
Session: ePoster Display
1806P - Analysis of germ-line mutations in non-syndromic malignancies with concurrent pathogenic variants in BRCA1, BRCA2, PALB2, ATM, CHEK2, and RAD51C/D
Presenter: Emily Miller
Session: ePoster Display
Resources:
Abstract
1807P - Pan-cancer analysis of SMARCA4 genomic alterations to reveal a complex molecular landscape
Presenter: Qinpeng Xie
Session: ePoster Display
820TiP - ENGOT-EN6/GOG-3031/NSGO-CTU-RUBY part 2: A phase III, randomized, double-blind, study of dostarlimab + carboplatin-paclitaxel followed by dostarlimab + niraparib versus placebo (PBO) + carboplatin-paclitaxel followed by PBO in recurrent or advanced endometrial cancer (EC)
Presenter: Mansoor Raza Mirza
Session: ePoster Display
821TiP - GREAT: A multicentric cohort of advanced ovarian cancer (AOC) treated in real life with prospective collection of clinical data, tumor sample, and biomarkers (tBRCA, HRD) including genomic putative theranostic markers: A GINECO study
Presenter: Thibault De La Motte Rouge
Session: ePoster Display
822TiP - BFR ESS: A randomized phase II trial from the GSF/GETO French group evaluating the impact of interruption versus maintenance of aromatase inhibitors in patients with advanced or metastatic low grade endometrial stromal sarcoma after at least 3 years of therapy
Presenter: Isabelle Ray-Coquard
Session: ePoster Display
Resources:
Abstract